Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 73.5 EUR 0.55% Market Closed
Market Cap: 1.3B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Pharma Mar SA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharma Mar SA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Pharma Mar SA
MAD:PHM
Income from Continuing Operations
€622k
CAGR 3-Years
-79%
CAGR 5-Years
N/A
CAGR 10-Years
-27%
Grifols SA
MAD:GRF
Income from Continuing Operations
€180.7m
CAGR 3-Years
-38%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Income from Continuing Operations
-€3.4m
CAGR 3-Years
0%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Income from Continuing Operations
-€3.1m
CAGR 3-Years
-8%
CAGR 5-Years
23%
CAGR 10-Years
N/A
No Stocks Found

Pharma Mar SA
Glance View

Market Cap
1.3B EUR
Industry
Biotechnology

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

PHM Intrinsic Value
31.23 EUR
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Pharma Mar SA's Income from Continuing Operations?
Income from Continuing Operations
622k EUR

Based on the financial report for Sep 30, 2024, Pharma Mar SA's Income from Continuing Operations amounts to 622k EUR.

What is Pharma Mar SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-27%

Over the last year, the Income from Continuing Operations growth was -93%. The average annual Income from Continuing Operations growth rates for Pharma Mar SA have been -79% over the past three years , and -27% over the past ten years .

Back to Top